Alkermes announced that it received a Refusal to File letter from the U.S. FDA regarding its New Drug Application for ALKS 5461, a once-daily investigational depression medicine.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.